Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive supranuclear palsy: where are we now?

David J Burn1, Andrew J Lees

  • 1University of Newcastle upon Tyne, Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk

The Lancet. Neurology
|July 10, 2003
PubMed
Summary

Progressive supranuclear palsy (PSP) is an adult-onset neurodegenerative disease often misdiagnosed. Research highlights tau protein

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Handwriting patterns in isolated rapid eye movement sleep behaviour disorder.

Journal of Parkinson's disease·2026
Same author

Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research.

Movement disorders clinical practice·2025
Same author

'Pathology is disease' Parkinson's mythology: The 'brain-first-body-first' case study.

Journal of Parkinson's disease·2025
Same author

Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.

Neurology and therapy·2025
Same author

Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS]).

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

The resurrection of apomorphine: A dopamine analogue comparable in potency to L-DOPA.

Parkinsonism & related disorders·2025

Area of Science:

  • Neurology
  • Neurodegenerative Diseases
  • Pathology

Background:

  • Progressive supranuclear palsy (PSP), also known as Steele-Richardson-Olszewski disease, is an adult-onset neurodegenerative disorder.
  • Key clinical features include early postural instability leading to falls and vertical supranuclear-gaze palsy.
  • Recent epidemiology suggests PSP is more common than previously thought and frequently misdiagnosed.

Purpose of the Study:

  • To provide an updated review of progressive supranuclear palsy.
  • To discuss diagnostic challenges and recent insights into PSP pathogenesis.
  • To highlight the need for novel therapeutic strategies.

Main Methods:

  • Review of recent epidemiological studies on PSP prevalence and diagnosis.
  • Analysis of current understanding of PSP molecular pathology, focusing on tau protein.
  • Evaluation of existing diagnostic methods and the search for biomarkers.

Main Results:

  • PSP is underrecognized and often misdiagnosed, presenting to various medical specialists.
  • Diagnosis currently relies heavily on clinical assessment, as biomarkers and specific imaging/neurophysiological techniques are not yet impactful.
  • Tau protein accumulation and tau-genotype susceptibility are crucial in PSP pathogenesis.

Conclusions:

  • Effective diagnostic biomarkers and treatments for PSP remain elusive.
  • Understanding tau pathology is key to unraveling PSP pathogenesis.
  • There is an urgent need for the development of effective therapies for progressive supranuclear palsy.

Related Experiment Videos